#United States #Chicago #Cancer Research #SPX-303 #SparX Biopharmaceutical

SparX Biopharmaceutical to Present Phase 1 Clinical Updates at AACR 2025

SparX Biopharmaceutical Corp. has exciting news for the oncology community. The company will deliver clinical updates on its leading therapeutic, SPX-303, at the esteemed 2025 Annual Meeting of the American Association for Cancer Research (AACR) on April 28. This presentation will take place during the Trial-in-Progress poster session, marking a significant milestone as it coincides with the one-year anniversary of SPX-303's first patient dosing in its ongoing Phase 1 clinical trial.

SPX-303 is a first-in-class bispecific antibody engineered to target both LILRB2 and PD-L1, two critical immune checkpoint proteins that cancer cells often exploit for survival. By simultaneously inhibiting these proteins, SPX-303 represents a novel approach that aims to activate both myeloid and T-cell immune responses, creating a powerful synergy in the fight against resistant or refractory solid tumors. Currently, this innovative therapy is enrolling patients at a dose level of 20 mg/kg.

Highlights of the Presentation

In addition to the poster presentation at McCormick Place in Chicago, attendees can expect a more comprehensive overview of SPX-303's dual mechanism of action. This will be featured during a Satellite Symposium titled "Harnessing Super Immunotherapy and ADCs to Redefine the Standard of Care," jointly hosted by the University of Illinois at Chicago Cancer Center and Yao Yuan—Academy for Pharma Innovation. The symposium aims to gather leading clinicians, academic researchers, and industry experts to discuss cutting-edge developments in next-generation immuno-oncology.

A focal point of this discussion will be the innovative combination of antibody-drug conjugates (ADCs) with checkpoint inhibitors, which aims to improve tumor-targeting precision and enhance immune responses against cancer. This combination approach is expected to deliver deeper and more durable anti-tumor responses compared to previous therapies.

The Promise of SPX-303

According to Dr. Gui-Dong Zhu, CEO of SparX, SPX-303 exemplifies a significant advancement in the strategies for macrophage checkpoint blockade and T-cell co-engagement. “This program holds promise as a revolutionary immuno-oncology therapy—termed 'Super IO'—for patients who have limited treatment options,” he stated.

Event Details

The SPX-303 poster will be showcased as Poster #CT116-11 during the Phase I Clinical Trials in Progress session from 2:00 PM to 5:00 PM. The Satellite Symposium will be hosted at the Trump International Hotel & Tower in Chicago, and SparX encourages attendees to visit their exhibition booth during the event. Early registration through the provided portal is advised to secure a seat at this anticipated symposium.

About SparX Biopharmaceutical Corp.

SparX Biopharmaceutical is a research-focused, development-stage biopharmaceutical company committed to pioneering innovative nanobody-based therapies. With a robust approach to global collaboration and scientific excellence, SparX aims to deliver next-generation treatments to patients around the world. By leveraging advanced platforms such as SAILING™ and proprietary Nab2 bi-ADC technology, the company drives meaningful innovation in drug development, from target identification through to clinical trials.

For more information on the SPX-303 study and details on its clinical trial, you can visit ClinicalTrials.gov.